The Global Chronic Granulomatous Disease Management Industry is on track for steady growth, with a projected expansion from US$1.31 billion in 2023 to US$2.11 billion by 2033. This translates to a Compound Annual Growth Rate (CAGR) of 4.9% over the forecast period (2023-2033).
Market Growth Driven by Increased R&D Efforts
Future Market Insights (FMI) attributes this anticipated growth to heightened research and development (R&D) initiatives by major pharmaceutical companies. A recent analysis by FMI, based on data from 2018 to 2022, revealed a historical CAGR of 3.3% in the CGD management market.
Several factors are expected to drive this growth, including an increased incidence of uncommon diseases, amplified healthcare expenditure in developed nations, and a surge in research and development endeavors. Lifestyle changes and dietary shifts are also anticipated to contribute to market expansion for chronic granulomatous disease treatment during the forecast period.
Request the Sample PDF Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16435
Furthermore, North America and Europe are two major regions contributing to the growth of the CGD management market. This is owing to the developed healthcare infrastructure and the presence of key players in the region. Furthermore, the progression of technology and increased government funding for the healthcare industry are expected to provide ample opportunities for the expansion of the market for the treatment of chronic granulomatous disease in the foreseeable future
Key Takeaways from the Global Chronic Granulomatous Disease (CGD) Management Industry Study
- By type, Trimethoprim is expected to possess a 40% market share for the CGD market in 2023.
- By end user, Hospitals are expected to hold 40% of the market share in 2023 for the Chronic Granulomatous Disease (CGD) management market.
- North America is expected to possess a 45% market share for the Chronic Granulomatous disease (CGD) management market in 2023.
- Europe’s Chronic Granulomatous Disease (CGD) management market size is expected to possess a 35% market share in 2023.
“Increase in research activities along with prevalence of rare diseases is a key driver for the CGD management market.” states an FMI analyst
Global Chronic Granulomatous Disease (CGD) Management Industry Competitive Landscape
- In July 2018, Clinigen Group plc acquired the global rights to Imukin from Horizon Pharma. The company is focusing on reducing the frequency of serious infections in patients with Chronic Granulomatous Disease (CGD)
- In January 2020, Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
Unlock Valuable Insights – Purchase Full Report Today
https://www.futuremarketinsights.com/checkout/16435
Key Companies Profiled:
- Clinigen Group plc
- Orchard Therapeutics plc2032
- Horizon Therapeutics plc
- Co. Ltd
- Bellicum Pharmaceuticals, Inc
- Pfizer Inc
- Hoffmann-La Roche Ltd
- Novartis AG
- Lonza
- GlaxoSmithKline plc
- Eli Lilly and Company
- Johnson & Johnson Services, Inc
- Merck KGaA
Key Segments Profiled in the Global Chronic Granulomatous Disease (CGD) Management Industry Survey
Type:
- X-Linked Chronic Granulomatous Disease
- Autosomal Recessive Chronic Granulomatous Disease
Diagnosis:
- Neutrophil Function Tests
- Genetic Testing
- Prenatal Testing
Treatment:
- Infection Management
- Trimethoprim
- Sulfamethoxazole
- Itraconazole
- Interferon-gamma
- Stem Cell Transplantation
- Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
